JP7208146B2 - ブルルリパーゼを含有する口腔内分散性錠剤を生産する方法およびブルルリパーゼを含む液体医薬組成物を生産する方法。 - Google Patents

ブルルリパーゼを含有する口腔内分散性錠剤を生産する方法およびブルルリパーゼを含む液体医薬組成物を生産する方法。 Download PDF

Info

Publication number
JP7208146B2
JP7208146B2 JP2019547658A JP2019547658A JP7208146B2 JP 7208146 B2 JP7208146 B2 JP 7208146B2 JP 2019547658 A JP2019547658 A JP 2019547658A JP 2019547658 A JP2019547658 A JP 2019547658A JP 7208146 B2 JP7208146 B2 JP 7208146B2
Authority
JP
Japan
Prior art keywords
lipase
burr
orodispersible tablet
orodispersible
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019547658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509052A5 (https=
JP2020509052A (ja
Inventor
フューラー リチャード
リューデマン ジャン
ギャレット リサ
Original Assignee
ノルドマルク ファーマ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノルドマルク ファーマ ゲーエムベーハー filed Critical ノルドマルク ファーマ ゲーエムベーハー
Publication of JP2020509052A publication Critical patent/JP2020509052A/ja
Publication of JP2020509052A5 publication Critical patent/JP2020509052A5/ja
Priority to JP2022151344A priority Critical patent/JP2022184994A/ja
Application granted granted Critical
Publication of JP7208146B2 publication Critical patent/JP7208146B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Botany (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Non-Alcoholic Beverages (AREA)
JP2019547658A 2017-03-03 2018-03-05 ブルルリパーゼを含有する口腔内分散性錠剤を生産する方法およびブルルリパーゼを含む液体医薬組成物を生産する方法。 Active JP7208146B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022151344A JP2022184994A (ja) 2017-03-03 2022-09-22 ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102017104472.8 2017-03-03
DE102017104472.8A DE102017104472A1 (de) 2017-03-03 2017-03-03 Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
PCT/EP2018/055285 WO2018158459A1 (de) 2017-03-03 2018-03-05 Schmelztablette enthaltend burlulipase und daraus hergestellte pharmazeutische zusammensetzung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022151344A Division JP2022184994A (ja) 2017-03-03 2022-09-22 ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス

Publications (3)

Publication Number Publication Date
JP2020509052A JP2020509052A (ja) 2020-03-26
JP2020509052A5 JP2020509052A5 (https=) 2021-04-15
JP7208146B2 true JP7208146B2 (ja) 2023-01-18

Family

ID=61628314

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019547658A Active JP7208146B2 (ja) 2017-03-03 2018-03-05 ブルルリパーゼを含有する口腔内分散性錠剤を生産する方法およびブルルリパーゼを含む液体医薬組成物を生産する方法。
JP2022151344A Pending JP2022184994A (ja) 2017-03-03 2022-09-22 ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022151344A Pending JP2022184994A (ja) 2017-03-03 2022-09-22 ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス

Country Status (9)

Country Link
US (1) US11464834B2 (https=)
EP (1) EP3525769B1 (https=)
JP (2) JP7208146B2 (https=)
CN (1) CN110612098B (https=)
CA (1) CA3055116C (https=)
DE (1) DE102017104472A1 (https=)
ES (1) ES2880602T3 (https=)
PL (1) PL3525769T3 (https=)
WO (1) WO2018158459A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017104480A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Wässrige Lösung von Burlulipase umfassend Kalziumionen
US20240000705A1 (en) * 2020-09-17 2024-01-04 Catalent U.K. Swindon Zydis Limited Use of surfactant with high molecular weight fish gelatin based dosage formulations to improve flow characteristics
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
DE102023200788A1 (de) 2023-01-31 2024-08-01 Technische Universität Braunschweig - Körperschaft des öffentlichen Rechts Festes Lyophilisat und Verfahren zur Herstellung

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502972A (ja) 2002-05-07 2006-01-26 フェリング ベスローテン フェンノートシャップ デスモプレシンの口腔内分散性医薬製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1642654C3 (de) 1968-01-16 1979-11-29 Centre Europeen De Recherches Mauvernay, C.E.R.M., Riom Verfahren zur mikrobiologischen Herstellung eines stabilen gereinigten Lipase-Präparates und pharmazeutisches Mittel, welches dieses enthält
DE2638088C3 (de) 1976-08-24 1979-06-21 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verwendung von SuBmolkenpulver
ES2059986T3 (es) 1989-03-08 1994-11-16 Simon Lodewijk Scharpe Una composicion para el tratamiento de la insuficiencia exocrina del pancreas, y el uso de dicha composicion.
ATE175117T1 (de) 1991-07-01 1999-01-15 Basf Ag Verwendung von lipasen zur herstellung von arzneimitteln
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6740339B1 (en) 1999-06-18 2004-05-25 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
US6588180B2 (en) 2001-02-02 2003-07-08 R. P. Scherer Technologies, Inc. Constricted neck blister pack and apparatus and method for making the same
CN1394607A (zh) 2002-08-07 2003-02-05 王登之 治疗心绞痛的黄杨宁口腔崩解片及其制备方法
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
WO2006044529A1 (en) 2004-10-14 2006-04-27 Altus Pharmaceuticals Inc. Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
ATE398444T1 (de) 2004-10-28 2008-07-15 Pantec Ag Herstellung einer rasch zerfallendenden festen darreichungsform ausgehend von einem pulver und einem gefriertrocknungsschritt
EP2328609A1 (en) 2008-08-26 2011-06-08 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
ES2488407T3 (es) * 2009-01-29 2014-08-27 Nordmark Arzneimittel Gmbh & Co. Kg Preparación farmacéutica que contiene lipasa de origen bacteriano
DE102009006594A1 (de) * 2009-01-29 2010-08-05 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutisches Präparat
WO2014166994A1 (en) 2013-04-09 2014-10-16 Danmarks Tekniske Universitet Nano-microdelivery systems for oral delivery of an active ingredient
CN104109662B (zh) * 2014-06-23 2017-03-01 华中科技大学 一种固定化的洋葱伯克霍尔德菌脂肪酶及其制备方法
DE102015114857A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Getränk, enthaltend eine pharmazeutische Zusammensetzung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006502972A (ja) 2002-05-07 2006-01-26 フェリング ベスローテン フェンノートシャップ デスモプレシンの口腔内分散性医薬製剤

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Badgujar, B. P., Mundada, A. S.，The technologies used for developing orally disintegrating tablets: a review，Acta Pharmaceutica，2011年，Vol.61, No.2，p.117-139，doi:10.2478/v10007-011-0020-8
ClinicalTrials.gov Identifier: NCT01710644，Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis，[online]，2016年06月07日，[retrieved on 2021.05.07]，Retrieved from the Internet:<URL:https://clinicaltrials.gov/ct2/show/NCT01710644>
Heubi, J. E. et al.，Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial，The Journal of Pediatrics，2016年，Vol.176，p.156-161，doi:10.1016/j.jpeds.2016.05.049
Kristensen, H. G.，WHO guideline development of paediatric medicines: points to consider in pharmaceutical development，International Journal of Pharmaceutics，2012年，Vol.435, No.2，p.134-135，doi:10.1016/j.ijpharm.2012.05.054
Stoltenberg, I., Breitkreutz, J.，Orally disintegrating mini-tablets (ODMTs) - a novel solid oral dosage form for paediatric use，European Journal of Pharmaceutics and Biopharmaceutics，2011年，Vol.78, No.3，p.462-469，doi:10.1016/j.ejpb.2011.02.005
Sznitowska, M. et al.，The physical characteristics of lyophilized tablets containing a model drug in different chemical forms and concentrations，Acta Poloniae Pharmaceutica，2005年，Vol.62, No.1，p.25-29
井阪 久美子，熊坂 治，小児用剤形と服薬アドヒアランス―ＯＤ錠・チュアブル錠の小児への適応を視野に入れて―，薬局，2013年，第64巻，第10号，p.2641-2649
米子 真記，海外の指針等における小児の製剤開発，薬局，2013年，第64巻，第10号，p.2619-2623

Also Published As

Publication number Publication date
EP3525769B1 (de) 2021-05-12
ES2880602T3 (es) 2021-11-25
PL3525769T3 (pl) 2021-10-25
CN110612098A (zh) 2019-12-24
DE102017104472A1 (de) 2018-09-06
JP2022184994A (ja) 2022-12-13
CN110612098B (zh) 2022-05-13
WO2018158459A1 (de) 2018-09-07
JP2020509052A (ja) 2020-03-26
CA3055116A1 (en) 2018-09-07
EP3525769A1 (de) 2019-08-21
CA3055116C (en) 2023-07-11
US20200009232A1 (en) 2020-01-09
US11464834B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
US20240245761A1 (en) Methods of treating celiac disease
JP2022184994A (ja) ブルルリパーゼを含有する口腔内分散性錠剤、ブルルリパーゼを含む液体医薬組成物を調製する方法および口腔内分散性錠剤を生産するプロセス
KR101968457B1 (ko) 장용 코팅된 저 강도 췌장 리파제 제제
US20100233218A1 (en) Combination enzyme for cystic fibrosis
TW200843795A (en) Stable digestive enzyme compositions
JP7554807B2 (ja) 消化障害の予防および／または処置用の医薬組成物およびそれを製造する方法、並びにそれを含む医薬製品
CA3055118C (en) Pharmaceutical composition comprising pancreatin and a lipase-containing coating
RU2068698C1 (ru) Лекарственное средство для лечения больных со сниженной внешнесекреторной функцией поджелудочной железы
US20060013807A1 (en) Rapidly disintegrating enzyme-containing solid oral dosage compositions
RU2276985C1 (ru) Фармацевтическая композиция для лечения заболеваний поджелудочной железы и расстройств пищеварения, связанных с заболеванием печени
HK1204450B (en) Methods of treating celiac disease
DE102017104501A1 (de) Pharmazeutische Zusammensetzung umfassend einen Träger und einen Überzug enthaltend wenigstens eine Lipase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210304

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210304

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20210726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220922

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221006

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230105

R150 Certificate of patent or registration of utility model

Ref document number: 7208146

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250